Other Mutations: PTCH

NCT05199584: A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

NCT05199584
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PTCH
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have a solid tumor that harbors a PTCH1 loss of function mutation
Exclusions: 
https://ClinicalTrials.gov/show/NCT05199584

NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, EGFR, HER2, MET, ALK, ROS, BRAF, PI3K, FGFR, mTOR, TSC, PTEN, NF1/2, GNA, SMO, PTCH, KIT, Akt, NRAS, CDK, Rb+, MLH, NTRK
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Any patient with a solid tumor is eligible; The trial matches patients to a specific experimental arm based on the mutations or molecular information of the tumor- see trial for full list of eligible mutations
Exclusions: Patients with brain metastases must have completed treatment, surgery or radiation therapy
https://clinicaltrials.gov/show/NCT02465060

Up ↑